Summary
The pharmacokinetics of doxorubicin has been studied in 26 sarcoma patients receiving polychemotherapy. Mean elimination half-life was 34.7±16.6 h and the total plasma clearance was 29.5±9.31·h−1·m−2. No relationship was found between the pharmacokinetic parameters and the response to treatment, or its toxicity. Special attention was paid to the early-phase kinetics of the drug (3–20 min after injection). A correlation between the early clearance and the ages of the patients was observed. The early clearance was clearly correlated with the total plasma clearance measured over 48 h after injection, indicating the importance of the distribution phase in the overall kinetics of the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Riggs CE, Bachur NR (1983) Clinical pharmacokinetics of anthracycline antibiotics. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam
Robert J, Vrignaud P, Eghbali H, Nguyen-Ngoc T, Hoerni B (1985) Tentative dose monitoring of doxorubicin in lymphoma patients. Med Oncol Tumor Pharmacother 2: 225–259
O'Bryan RM, Baker LH, Gottlieb JE et al. (1977) Dose-response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948
Bui NB, Chauvergne J, Hocke C, Durand M, Brunet R, Coindre JM (1985) Analysis of a series of sixty soft-tissue sarcomas in adults treated with a cyclophosphamide — vincristine — adriamycin — dacarbazine (CYVADIC) combination. Cancer Chemother Pharmacol 15: 82–85
Robert J, Iliadis A, Hoerni B, Cano JP, Durand M, Lagarde C (1982) Pharmacokinetics of doxorubicin in patients with breast cancer. Correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18: 739–745
Vrignaud P, Londos-Gagliardi D, Robert J (1986) Cellular pharmacology of doxorubicin in sensitive and resistant glioblastoma cells in culture. Oncology 43: 60–66
Trojani M, Contesso G, Coindre JM et al. (1984) Soft tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33: 37–42
Robert J, Hoerni B, Vrignaud P, Lagarde C (1983) Earlyphase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters. Cancer Chemother Pharmacol 10: 115–119
Robert J (1980) Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liq Chromatogr 3: 1561–1572
Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1978) Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liq Chromatogr 1: 795–809
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, USA
Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37: 1416–1420
Gil P, Favre R, Durand A, Iliadis A, Cano JP, Carcassonne Y (1982) Time-dependency of adriamycin pharmacokinetics. Cancer Chemother Pharmacol 10: 120–124
Robert J, Vrignaud P, Iliadis A, Eghbali H, Hoerni B (1983) Etude pharmacocinétique de la doxorubicine dans le traitement des lymphomes malins non Hodgkiniens. Nouv Rev Fr Hematol 25: 91–95
Robert J, Hoerni B (1983) Age-dependence of the early clearance of doxorubicin. Cancer Res 43: 4467–4469
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robert, J., Bui, N.B. & Vrignaud, P. Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31, 695–699 (1987). https://doi.org/10.1007/BF00541297
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541297